azithromycin / Generic mfg. - LARVOL DELTA

Drug-Induced Vanishing Bile Duct Syndrome: A Disproportionality Analysis Using the FDA Adverse Event Reporting System (FAERS) Database (ACG 2025) - "A total of 899 cases of VBDS were reported to the FAERS from 2003-2024. 893 were characterized as severe, including 166 deaths (18.6%). The most common reported drugs were – Ibuprofen (11.12%; ROR: 32.35 [26.28, 39.83]; p< 0.05), Sulfamethoxazole/Trimethoprim (9.12%; ROR: 63.23 [50.38, 79.37]; p< 0.05), Ciprofloxacin (7.00%; ROR: 37.87 [29.31, 48.92]; p< 0.05), Lamivudine with and without Zidovudine (6.1%; ROR: 59.38 [45.2, 78.02]; p< 0.05), Azithromycin (5.5%; ROR: 59.21 [44.51, 78.78]; p< 0.05), Temozolomide (5.12%; ROR: 66.57 [49.47, 89.59]; p< 0.05), Nevirapine (4.89%; ROR: 117.62 [86.83, 159.33]; p< 0.05), Levofloxacin (4.67%; ROR: 25.06 [18.39, 34.17]; p< 0.05), Acetaminophen (4.67%; ROR: 9.14 [6.7, 12.46]; p< 0.05), Levetiracetam (4.67%; ROR: 19.02 [13.95, 25.93]; p< 0.05), Lamotrigine (4.00%; ROR: 15.64 [11.2, 21.82]; p< 0.05), and Prednisone (3.78%; ROR: 6.72 [4.77, 9.47]; p< 0.05). Ibuprofen was the most reported drug as a..."

Adverse events • Cholestasis • Hepatology

A Rare Case of Hepatitis B Reactivation in a Patient Treated With Regorafenib for Gastrointestinal Stromal Tumor: A Case Report (ACG 2025) - "She was started on azithromycin, ethambutol, and rifampin...Tenofovir was initiated but discontinued due to Fanconi syndrome; she was transitioned to entecavir...This case underscores the importance of routine HBV screening and prophylaxis prior to initiating immunosuppressive or targeted cancer therapies. Early identification and management of HBV reactivation are crucial to prevent life-threatening hepatic complications.Figure: HBV Viral Load Timeline"

Case report • Clinical • Stroma • Breast Cancer • Cough • Fibrosis • Gastrointestinal Cancer • Gastrointestinal Stromal Tumor • Hepatitis B • Hepatology • Immunology • Infectious Disease • Liver Failure • Nephrology • Oncology • Respiratory Diseases • Sarcoma • Solid Tumor

A Rare Case of Immune Checkpoint Inhibitor Esophagitis Due to Pembrolizumab (ACG 2025) - "We describe a case of grade 3/4 pembrolizumab-induced esophagitis and mucositis in a patient receiving treatment for stage IIA breast adenocarcinoma.Case Description/ A 72-year-old female with triple-negative, poorly differentiated stage IIA breast adenocarcinoma achieved complete response to neoadjuvant therapy (doxorubicin, cyclophosphamide, and pembrolizumab)...Her symptoms proved refractory to empiric therapies including azithromycin, nystatin, fluconazole, micafungin, and saline gargles...Flexible laryngoscopy confirmed ulcerative mucositis with concomitant laryngopharyngitis.Pembrolizumab was discontinued, and she was initiated on prednisone 1 mg/kg, achieving significant pain improvement within one week...Treatment with fluconazole and pantoprazole was initiated...Management includes acid suppression (PPIs, H2 blockers), mucosal protectants (sucralfate), and corticosteroids for moderate to severe cases. This case highlights the need for clinician awareness of rare..."

Checkpoint inhibition • Clinical • Breast Cancer • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Mucositis • Oncology • Triple Negative Breast Cancer

Is It Time to Consider Hydroxyurea as a Potential Therapeutic Option in the Management of Malignant Pertussis - A Case Report and Literature Review. (PubMed, Cureus) - "A diagnosis of malignant pertussis, based on the severe paroxysmal cough, significant lymphocytosis, and progressive respiratory symptoms, was established, and treatment was initiated with azithromycin and hydroxyurea (20 mg/kg/day) under intensive supportive care. Early administration in hemodynamically stable patients may reduce the need for invasive procedures; however, its use in more severe cases requiring urgent leukoreduction may be limited due to the delayed onset of action. This case adds to the limited number of reported instances where hydroxyurea was successfully used as a noninvasive leukoreductive option in malignant pertussis."

Journal • Cardiovascular • Cough • Hypertension • Infectious Disease • Pertussis • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Treatment updates in post-infectious bronchiolitis obliterans (MTS 2025) - "Early use (within 3 weeks to 3 months of illness) of pulse IV Methylprednisolone at doses > 10 mg/kg/day x 3 days...Fluticasone, Azithromycin + Montelukast or FAM therapy: this has been extrapolated from treatment of Bronchiolitis Obliterans Syndrome (post-transplant) although there is little evidence to support its use in PiBO...Supportive care cannot be underestimated: includes administering oxygen as needed, bronchodilators, respiratory physiotherapy, antibiotics in cases of acute respiratory infections, diuretics in some patients, immunizations for pneumococcus and influenza, adequate nutrition, and avoidance of tobacco smoke or other inhaled drugs. Research into the role of microRNAs(miRNAs) is promising and upcoming, demonstrating its role in dysregulated inflammation, and this may lead to more effective therapeutic options."

Infectious Disease • Inflammation • Influenza • Pulmonary Disease • Respiratory Diseases • IL1B

Disseminated Gonococcal Infection Developing Two Days After Initial Eculizumab Administration in a Patient with Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review. (PubMed, J Infect Chemother) - "Antimicrobial susceptibility testing revealed elevated minimum inhibitory concentrations (MICs) for penicillin G, ciprofloxacin, azithromycin, and minocycline, whereas the MIC for ceftriaxone remained low. Following the patient's refusal to continue eculizumab therapy, the patient has chosen inebilizumab, resulting in stable management of NMOSD symptoms...This is a case of DGI in a patient with NMOSD, and the earliest reported onset of DGI following eculizumab initiation. Clinicians should remain vigilant for invasive gonococcal infections, even shortly after initiating complement-inhibiting therapy."

Journal • CNS Disorders • Complement-mediated Rare Disorders • Hematological Disorders • Infectious Disease • Meningococcal Infections • Neuromyelitis Optica Spectrum Disorder • Pain • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • CRP

Babesiosis-induced warm autoimmune hemolytic anemia, from infection to hemolysis: a case report. (PubMed, J Med Case Rep) - "Given the increasing prevalence of tick-borne illnesses, physicians should have a high index of suspicion for concurrent warm autoimmune hemolytic anemia in patients with babesiosis and anemia not improving with typical therapies. In addition, the interplay between babesiosis and warm autoimmune hemolytic anemia underscores the need for clinicians to consider infectious etiologies in the workup of this disease."

Journal • Review • Anemia • Autoimmune Hemolytic Anemia • Hematological Disorders • Immunology • Infectious Disease

Malignant Peritoneal Mesothelioma Masquerading as Sclerosing Mesenteritis (ACG 2025) - "The patient was then started on prednisone to treat suspected sclerosing mesenteritis...Given her positive response to therapy, she was started on azithromycin as maintenance therapy for sclerosing mesenteritis...After receiving 4 cycles of pemetrexed and cisplatin with complications, the patient acknowledged that her cancer was incurable and prioritized maintaining her quality of life. This case highlights the diagnostic challenges of MPM in its early stage because it can resemble sclerosing mesenteritis in terms of symptoms and imaging findings. Accurate diagnosis with close follow-up to monitor the patient's symptoms and imaging findings in response to therapy is essential for improved patient outcomes."

Esophageal Cancer • Fibrosis • Mesothelioma • Peritoneal Mesothelioma • Solid Tumor

3D collagen high-throughput screen identifies drugs that induce epithelial polarity and enhance chemotherapy response in colorectal cancer. (PubMed, Commun Biol) - "A retrospective analysis of patient data demonstrated that the use of azithromycin in patients undergoing treatment for CRC with irinotecan had improved the 5 year survival compared to the chemotherapy alone. These results highlight the importance of morphological screens to identify novel drug candidates and synergistic mechanisms."

Journal • Colorectal Cancer • Oncology • Solid Tumor • CDH1 • TJP1

1118: COPD Management: Advanced Pharmacological Options (CHEST 2025) - "This session will address medication class selection in COPD highlighting considerations for newly approved options (ensifentrine and dupilumab) and how they fit in with existing therapies. Review the evidence for ensifentrine, roflumilast, and azithromycin and provide a framework for drug selection 3. Learn about the currently available and emerging biologic therapeutics in the management of COPD"

Metastases • Chronic Obstructive Pulmonary Disease • Eosinophilia • Immunology • Respiratory Diseases

Colobronchial Fistula Complicating Severe Crohn's Colitis (ACG 2025) - "Stool studies were negative for C. difficile but positive for Shigella and Campylobacter and Azithromycin was initiated...Infliximab was initiated at 5 mg/kg and steroids were avoided...He rapidly improved, remained on oral vancomycin, and a diet was resumed. Albumin had improved to 2.1, TPN and broad spectrum antibiotics were discontinued, and azathioprine 50 mg was added...At 1 year follow-up, he maintained a normal weight, had good ileostomy function, and was attending college. This case underscores the importance of recognizing inflammatory colitis, aggressive medical therapy, and a multidisciplinary approach to care of complex IBD patients.Figure: Image. Trans-diaphragmatic fistula extending from the splenic flexure to left lower lobe bronchus."

Cardiovascular • Cough • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Immunology • Inflammatory Bowel Disease • Pulmonary Disease • Respiratory Diseases

Volatile organic compounds in patients with primary ciliary dyskinesia with or without prophylactic azithromycin (ERS 2025) - No abstract available

Clinical • Otorhinolaryngology • Respiratory Diseases

Fucoidan-coated liposomes with azithromycin and curcumin: a novel approach to treat inflammatory lung diseases (ERS 2025) - No abstract available

Inflammation • Pulmonary Disease • Respiratory Diseases

Azithromycin vs. Doxycycline in Community-Acquired Pneumonia; An Analysis of Clinical Outcomes from the MIMIC IV Database (ERS 2025) - No abstract available

Clinical • Clinical data • Infectious Disease • Pneumonia • Respiratory Diseases

Rifampicin leads to subtherapeutic azithromycin exposures in NTM disease treatment (ERS 2025) - No abstract available

Respiratory Diseases

Azithromycin prophylaxis how long is too long? (ERS 2025) - No abstract available

Azithromycin and oesophageal motility in chronic respiratory disease: a feasibility trial (ERS 2025) - No abstract available

Respiratory Diseases

Prophylactic azithromycin in preventing recurrent acute exacerbations of COPD and blood eosinophil counts: a hospital review (ERS 2025) - No abstract available

Clinical • Review • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Eligibility for Prophylactic Azithromycin in individuals with COPD attending pulmonary rehabilitation (ERS 2025) - No abstract available

Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Respiratory Diseases

Azithromycin and continuous cough monitoring: an open-label trial (ERS 2025) - No abstract available

Clinical • Cough • Respiratory Diseases

Transcriptomic effects of Azithromycin on airway basal cells in CCDC39 primary ciliary dyskinesia (ERS 2025) - No abstract available

Otorhinolaryngology • Respiratory Diseases

Antibiotic therapies in chronic paediatric lung diseases: evidence and impact (ERS 2025) - "The evidence for prophylactic antibiotic therapies (including azithromycin, anti-staphylococcal, trimethoprim/sulfamethoxazole) to prevent respiratory infections in chronic pediatric lung diseases will be discussed. The impact of these therapies on the microbiome and potential risks, such as antibiotic resistance, will also be addressed."

Infectious Disease • Pediatrics • Pulmonary Disease • Respiratory Diseases

Molecular Detection of Mutations in the penA and 23S rRNA Genes of Neisseria gonorrhoeae Related to Decreased Cephalosporin and Azithromycin Susceptibility in Rectal Specimens from Men Who Have Sex with Men (MSM) in Lima, Peru. (PubMed, Trop Med Infect Dis) - "Finally, sequencing of the penA gene in the 27 samples revealed mutations related to decreased susceptibility to cephalosporins. This study identified genetic mutations conferring resistance to azithromycin and decreased susceptibility to cephalosporins, providing an overview of the circulating mutations conferring resistance in N. gonorrhoeae strains in Peru."

Journal • Infectious Disease

VIVANT: Vitality in Infants Via Azithromycin for Neonates Trial (clinicaltrials.gov) - P4 | N=4000 | Not yet recruiting | Sponsor: University of California, San Francisco | Trial completion date: Jan 2029 ➔ Apr 2030 | Trial primary completion date: Jan 2029 ➔ Apr 2030

Trial completion date • Trial primary completion date • Infectious Disease

Effects of Different Antibiotic Regimens in Preterm Premature Rupture of Membranes (clinicaltrials.gov) - P=N/A | N=40 | Completed | Sponsor: Yuzuncu Yıl University

New trial